Publications by authors named "Gregory Strabach"

Claim this Profile
T
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
Dorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, Takeshi Kadokura, Marten Heeringa

Clin Pharmacol Drug Dev· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Walter Krauwinkel, James Dickinson, Marloes Schaddelee, John Meijer, Reiner Tretter, Gregory Strabach

Eur J Drug Metab Pharmacokinet· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Pharmacokinetic Interaction Between the β3 -Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects.
Walter J J Krauwinkel, Virginie M M Kerbusch, John Meijer, Reiner Tretter, Gregory Strabach

Clin Pharmacol Drug Dev· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.
Dorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, Takeshi Kadokura, Marten Heeringa

Br J Clin Pharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Walter Krauwinkel, Jan van Dijk, Marloes Schaddelee, Charlotte Eltink, John Meijer, Grégory Strabach

Clin Ther· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis